ClinicalTrials.gg
RecruitingNCT05903352CAT-CAPUpdated Mar 20, 2025

Customized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia

A Phase 3 interventional study of Stop antibiotic and Continue the antimicrobial treatment in Community-Acquired Pneumonia, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Community-Acquired Pneumonia with a site in France — 11 open to participants now, 11 under way, 5 of them phase 3. Community-Acquired Pneumonia · France.

Planned enrollment
13th of 26
328 · median 327
Started
2024
with 3 others
Phase 3
9 of 40
5 open now
Primary completion
2027-05
later than 3 of 10 live
Registered
32nd of 40
by date
Lead sponsor
6 of 40
Assistance Publique - Hôpitaux de Paris

Among the 40 studies in Community-Acquired Pneumonia with a site in France, this one is the 13th largest by planned enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2024, is one of 9 in phase 3, reaches primary completion later than 3 of the 10 other live ones, and was the 32nd registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

11 of the 40 studies in Community-Acquired Pneumonia with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Community-Acquired Pneumonia with a site in France, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate if the efficacy of an experimental strategy on antibiotic treatment duration based on stopping treatment when stability criteria are reached after at least 48 h of treatment, is non-inferior to the efficacy of standard antibiotic duration in CAP patients treated in the hospital setting.

As the secondary objectives, the study aims

  • To study if the efficacy of our experimental strategy on antibiotic treatment duration compared to standard of care in CAP patients treated in the hospital setting is non-inferior in terms of:

    • Persistence of cure at Day 30 of antibiotic treatment
    • All-cause mortality rate on Day 30 of antibiotic treatment
    • Patients evolution of pneumonia symptoms and quality of life via 2 scores (CAP score, CAP Sym) at Day 0 of treatment (retrospectively), at stability (Day S), at Day 7 , at Day 15, and at Day 30 of antibiotic treatment.
  • To compare between the 2 study arms at Day 30 of antibiotic treatment:

    • The duration of antibiotic treatment;
    • The length of hospital stay;
    • The frequency and severity of adverse events during the 30 days after the start of treatment.
  • To explore the impact of reduced antibiotic treatment duration for CAP on the oropharyngeal resistome.
Read the detailed description

Recent studies have suggested that community-acquired pneumonia (CAP) can be successfully treated with short-course antibiotic regimen when clinical improvement is rapidly obtained. Even if clinical response is obtained in 3 days in the majority of cases, it can vary widely among patients suggesting "one duration does not fit all". An individualised duration of therapy depending on the patient's response could help to ensure bacterial eradication while avoiding unnecessary antibiotic exposure and thus reduce antibiotic resistance. At present, this strategy has never been tested.

This is a phase III, pragmatic, non-inferiority randomised (1:1) national multicentre trial. Population of study participants will be patients admitted to hospital with suspected CAP and in need for antibiotics.

There is no need to establish a DSMB for this trial. The antibiotic treatments prescribed during this study are treatments used in current practice, with well-known adverse drug reactions. Furthermore, a 3-day treatment duration has already been studied in 2 previous randomized clinical trials, showing its safety for hospitalized CAP.

Statistical analysis:

Statistical inference for non-inferiority will be based on the confidence intervals (CI) of the difference in Day 15 cure proportions [proportion in reference arm - proportion in experimental arm] accounting for randomisation stratification factors (centre and delay from Day 0 to Day S (≤ 3 days or > 3 days).

The inferiority hypothesis will be rejected and non-inferiority will be claimed if the upper bound of the 95%CI of the difference is ≤ 10%.

Secondary efficacy endpoints evaluating the evolution of symptoms will be analysed using either a GMM or a GEE for categorical and continuous variables, respectively.

Other quantitative variables will be compared using the Student t-test (or a non-parametric test if the distribution remains skewed following transformation), while categorical variables will be analysed using either the Chi-squared or the Fisher-exact tests.

All statistical tests will be performed with a level of significance of 5%, except the primary endpoint which be analysed with a 2.5% level of significance.

03

Conditions studied

  • Community-Acquired Pneumonia

Keywords

  • Community-Acquired Pneumonia
  • Antibiotic treatment duration
  • Antibiotic resistance
  • Infectious diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (≥18 years old)
  • Admitted to hospital for suspected CAP defined by the presence of at least 2 of the following diagnostic clinical criteria:

    • Fever (temperature > 38°C) or hypothermia (\< 36°C)
    • Dyspnea
    • Cough
    • Production of purulent sputum
    • Crackles
  • Radiological evidence of a new infiltrate (chest X-ray or CT scan)
  • Negative viral respiratory testing
  • Treated for a minimum of 48 hours with antibiotics (excluding azithromycin due to its prolonged half-life)Presenting with an early clinical response within the last 24 hours (up to 7 days after the start of antibiotic treatment, if planned treatment duration > 7 days), defined by the presence of all the following criteria:apyrexia (T°C ≤ 37.8)heart rate \< 100/minrespiratory rate \< 24/min, according to the patient's usual mode of oxygenation,arterial oxygen saturation ≥ 92%, according to the patient's usual mode of oxygenation,Patient currently under antibiotic treatment for his suspected CAP (i.e. the last dose of ATB has been administered to the patient less than 24 hours ago)
  • Patient presenting a clinical response within the last 24 hours defined by the presence of all the following criteria:

    • apyrexia (T°C ≤ 37.8)
    • heart rate \< 100/min
    • respiratory rate \< 24/min, according to the patient's usual mode of oxygenation,
    • arterial oxygen saturation ≥ 92%, according to the patient's usual mode of oxygenation,
    • systolic blood pressure ≥ 90mmHg, The last occurring of these criteria must have appeared within the last 24 hours.
  • The antibiotic treatment for suspected CAP has started at least 48 hours ago and at most 6 days ago
  • No other site of infection besides respiratory
  • Affiliated to Health insurance
  • Has given
  • Patient understanding oral and written French, or presence of a relative who can explain and help him complete the study documents

Exclusion criteria

Exclusion Criteria:

  • Signs of severe CAP (abscess, massive pleural effusion, serious chronic respiratory insufficiency)
  • Known (asplenia, neutropenia, agammaglobulinemia, transplant, myeloma, lymphoma, known and CD4\<200/mm3)
  • Suspected or confirmed legionellosis
  • Any other infection necessitating concomitant antibiotic treatment
  • Confirmed or suspected aspiration pneumonia or healthcare-associated pneumonia
  • Treatment of suspected CAP with azithromycin (due to its prolonged half-life)
  • Concomitant treatment (only for patients treated with fluoroquinolones antibiotics)
  • Pre-existing aortic aneurysm or dissection, family history of aortic aneurysm or dissection, Marfan syndrome, Ehlers-Danlos syndrome, Takayasu arthritis, uncontrolled arterial hypertension, atherosclerosis (only for patients treated with fluoroquinolones antibiotics)
  • Pregnant or breastfeeding woman
  • \< 1 month
  • Patient under legal guardianship (French "tutelle" or "curatelle")
  • Patient without fixed address
  • Patient enrolled in another interventional clinical trial on CAP treatment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
328 participants (estimated)

Study arms

  • Placebo comparator
    Antibiotic treatment

    Antibiotic treatment duration left to the physician's judgment (usual practice: total treatment duration between 5 to 10 days according to French guidelines; more than 7 days of treatment should be justified).

    Drug: Continue the antimicrobial treatment

  • Experimental
    Interruption of treatment

    Interruption of treatment based on the patient reaching all of the following stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure \> 90mmHg; oxygen saturation ≥ 92%; respiratory rate \< 24/min; normal mental status (27)), with a treatment duration no shorter than 48 h.

    Other: Stop antibiotic

Interventions

  • OtherStop antibiotic

    Stop the antibiotic treatment on day S (stability criteria reached for 24 h or within 48 hours after the start of antibiotic treatment).

  • DrugContinue the antimicrobial treatment

    Continue the antimicrobial treatment for a duration predetermined by the investigator (usual practice, at least 5 days of treatment in total).

06

What researchers measure

Primary outcomes

  1. Rate of cure at Day 15 after treatment initiation

    Cure at Day 15 will be defined by the association of: * Persistence of stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure \> 90mmHg; oxygen saturation ≥ 92%; respiratory rate \< 24/min; normal mental status); * No additional antibiotic treatment, targeting CAP, taken after the end of initial antibiotic treatment. Patients who died, or are not cured as defined above, will be classified as failure at Day 15.

    Time frame: Day 15

Secondary outcomes

  1. Rate of cure at Day 30

    Rate of cure at Day 30 after the start of treatment defined by the association of: persistence of stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure \> 90mmHg; O2 saturation ≥ 92%; respiratory rate \< 24/min; normal mental status); absence of additional antibiotic treatment needed after the end of initial antibiotic treatment.

    Time frame: Day 30

  2. Mortality on Day 30

    All-cause mortality on Day 30 after the start of antibiotic treatment.

    Time frame: Day 30

  3. Patients' evolution of pneumonia symptoms

    Patients' evolution of pneumonia symptoms by CAP Score at Day 0 of treatment (retrospectively), at stability (Day S), at Day 7, at Day 15, and at Day 30 of antibiotic treatment.

    Time frame: Day-0, Day S, Day 7, at Day 15, and at Day 30

  4. Patients' evolution of pneumonia symptoms

    Patients' evolution of pneumonia symptoms and quality of life by CAP Sym: validated self-questionnaires filled at Day 0 of treatment (retrospectively), at stability (Day S), at Day 7, at Day 15, and at Day 30 of antibiotic treatment.

    Time frame: Day 15 and Day 30

  5. Duration of antibiotic treatment targeting CAP

    Duration of antibiotic treatment targeting CAP during the 30 days after the start of treatment.

    Time frame: Day 30

  6. Duration of antibiotic treatment for all indications

    Duration of antibiotic treatment for all indications during the 30 days after the start of treatment.

    Time frame: Day 30

  7. Length of hospitalization

    Length of initial hospital stay

    Time frame: Day 30

  8. Incidence of adverse event

    Frequency and severity of adverse events during the 30 days after the start of treatment

    Time frame: Day 30

  9. Number of resistance genes

    Calculating for each patient, the number of resistance genes normalised against the quantity of total bacterial DNA, the bacterial richness and diversity, among 300 patients.

    Time frame: Day S and Day 30

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Dinh A, Ropers J, Duran C, Davido B, Deconinck L, Matt M, Senard O, Lagrange A, Makhloufi S, Mellon G, de Lastours V, Bouchand F, Mathieu E, Kahn JE, Rouveix E, Grenet J, Dumoulin J, Chinet T, Pepin M, Delcey V, Diamantis S, Benhamou D, Vitrat V, Dombret MC, Renaud B, Perronne C, Claessens YE, Labarere J, Bedos JP, Aegerter P, Cremieux AC; Pneumonia Short Treatment (PTC) Study Group. Discontinuing beta-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet. 2021 Mar 27;397(10280):1195-1203. doi: 10.1016/S0140-6736(21)00313-5. PubMed 33773631 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for May 2027, 39 months after the start.

Of 20 phase 3 interventional studies under Community-Acquired Pneumonia, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 64. This study's planned 39 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2023
First posted
Jun 15, 2023
StartActual
Feb 5, 2024
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05903352
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Feb 5, 2024
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Mar 20, 2025

Study contacts

Aurélien Dinh, MD, PhD
Contact
aurelien.dinh@aphp.fr
+ 33 (0)1 47 10 44 32
Jacques Ropers, PharmD
Contact
jacques.ropers@aphp.fr
+ 33 01 42 16 03 48
Aurélien Dihn, MD, PhD
principal investigator · Infectious diseases department, Raymond-Poincaré Hospital - APHP
Jacques Ropers, PharmD
study director · Clinical Research Unit Pitié Salpêtrière - Charles Foix, CHU La Pitié-Salpêtrière - APHP

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion